{
    "clinical_study": {
        "@rank": "164805", 
        "arm_group": [
            {
                "arm_group_label": "BI 144807 PfoS Treatment A", 
                "arm_group_type": "Experimental", 
                "description": "intermediate dose of BI 144807"
            }, 
            {
                "arm_group_label": "BI 144807 PfoS Treatment C", 
                "arm_group_type": "Experimental", 
                "description": "high dose of BI 144807"
            }, 
            {
                "arm_group_label": "BI 144807 Tab Treatment B", 
                "arm_group_type": "Experimental", 
                "description": "intermediate dose of BI 144807"
            }, 
            {
                "arm_group_label": "BI 144807 Tab Treatment D", 
                "arm_group_type": "Experimental", 
                "description": "high dose of BI 144807"
            }, 
            {
                "arm_group_label": "BI 144807 Tab Treatment E", 
                "arm_group_type": "Experimental", 
                "description": "intermediate dose of BI 144807, fasted"
            }, 
            {
                "arm_group_label": "BI 144807 Tab Treatment F", 
                "arm_group_type": "Experimental", 
                "description": "intermediate dose of BI 144807, fed"
            }, 
            {
                "arm_group_label": "BI 144807 Tab Treatment G", 
                "arm_group_type": "Experimental", 
                "description": "intermediate dose of BI 144807, fasted"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to investigate the relative bioavailability of a BI 144807\n      tablet formulation compared to the oral solution formulation after single dose\n      administration (intermediate and high dose) under fasted conditions. Further objectives are\n      to assess whether and to what extent food affects single dose pharmacokinetics of BI 144807\n      administered as tablet, and to compare the relative bioavailability of two different tablet\n      formulations."
        }, 
        "brief_title": "Clinical Drug Trial in Healthy Male Subjects to Determine and Compare the Blood Concentrations of BI 144807 Following Administration as Oral Solution and Tablet Under Fasted and Fed Conditions", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        - Healthy male subjects\n\n        Exclusion criteria:\n\n        - Any relevant deviation from healthy condition"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01897597", 
            "org_study_id": "1313.9", 
            "secondary_id": "2013-000258-23"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI 144807 PfoS Treatment C", 
                "description": "oral solution", 
                "intervention_name": "BI 144807 high dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 144807 Tab Treatment F", 
                "description": "tablet", 
                "intervention_name": "BI 144807 intermediate dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 144807 Tab Treatment E", 
                "description": "tablet", 
                "intervention_name": "BI 144807 intermediate dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 144807 Tab Treatment G", 
                "description": "tablet", 
                "intervention_name": "BI 144807 intermediate dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 144807 Tab Treatment B", 
                "description": "tablet", 
                "intervention_name": "BI 144807 intermediate dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 144807 PfoS Treatment A", 
                "description": "oral solution", 
                "intervention_name": "BI 144807 intermediate dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 144807 Tab Treatment D", 
                "description": "tablet", 
                "intervention_name": "BI 144807 high dose", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "September 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Biberach", 
                    "country": "Germany"
                }, 
                "name": "1313.9.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "7", 
        "official_title": "An Open-label, Single Dose, Randomised, Crossover Trial in Healthy Male Subjects to Investigate the Relative Bioavailability of Tablet and Oral Solution of Two Doses of BI 144807 and Relative Bioavailability of BI 144807 When Administered as Tablet Under Fed and Fasted Conditions", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }, 
            {
                "measure": "Maximum measured concentration of the analyte in plasma (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01897597"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)", 
            "safety_issue": "No", 
            "time_frame": "48 hours"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}